Evidence map›Paper›PMID 39277207›Full record

ArticleBMJ open2024

Temporal trends in mortality and causes of death in patients with incident atrial fibrillation: a nationwide register study from 2010 to 2018.

Elis Kouki, Birgitta Salmela, Aapo Aro, Olli Halminen, Konsta Teppo, Jari Haukka, Jukka Putaala, Mika Linna, Pirjo Mustonen, Juha Hartikainen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elis KoukiUniversity of Helsinki Faculty of Medicine, Helsinki, Finland elis.kouki@helsinki.fi.ORCID 0000-0002-5759-0916
Birgitta SalmelaHeart Center, Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland.
Aapo AroHeart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland.
Olli HalminenAalto University, Espoo, Finland.
Konsta TeppoTYKS Turku University Hospital, Turku, Finland.
Jari HaukkaUniversity of Helsinki, Helsinki, Finland.ORCID 0000-0003-1450-6208
Jukka PutaalaUniversity of Helsinki, Helsinki, Finland.ORCID 0000-0002-6630-6104
Mika LinnaAalto University, Espoo, Finland.
Pirjo MustonenTYKS Turku University Hospital, Turku, Finland.
Juha HartikainenKuopio University Hospital, Kuopio, Finland.
Juhani K E AiraksinenTYKS Turku University Hospital, Turku, Finland.ORCID 0000-0002-0193-568X
Mika LehtoHeart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland.ORCID 0000-0002-8691-5142

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAtrial fibrillation (AF) is associated with increased mortality. Previous studies have reported conflicting results in temporal trends of mortality after AF diagnosis. We aim to address this disparity by investigating the 1-year mortality and causes of death in Finnish patients diagnosed with AF between 2010 and 2017.

designThe Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study is a nationwide retrospective register-based cohort study.

settingThe FinACAF study has gathered information on all Finnish AF patients between 2004 and 2018, with information from all national healthcare registers and data from all levels of care (primary, secondary and tertiary care).

participantsWe included patients with an incident AF diagnosis (International Classification of Diseases, 10th Revision code I48) between 2010 and 2017. To ensure a cohort of only incident AF, we excluded patients who used any oral anticoagulant during the year before cohort entry as well as patients with a recorded use of warfarin between 2004 and 2006. Patients under 20 years of age were excluded, and patients with permanent migration abroad before 1 January 2019 were excluded, N=157 658. PRIMARY OUTCOME MEASURES: 1-year all-cause, cardiovascular (CV) and cause-specific mortality following AF diagnosis.

resultsThe study cohort consisted of 157 658 incident AF cases (50.1% male, mean age 72.9 years). Both all-cause and CV mortality declined from cohort entry years 2010-2017 (from 12.9% to 10.6%, mortality rate ratio (MRR) 0.77; 95% CI 0.73 to 0.82 in cohort entry year 2017 with 2010 as reference; and from 7.4% to 5.2%, MRR 0.68; 95% CI 0.63 to 0.74, respectively). Overall mortality and CV mortality were lower in women than in men throughout the study period (MRR 0.66; 95% CI 0.63 to 0.69 and MRR 0.53; 95% CI 0.50 to 0.56, respectively). Deaths attributable to ischaemic heart disease decreased during the study period (from 30.7% to 21.6%, MRR 0.51; 95% CI 0.49 to 0.62 in 2017 vs 2010), whereas dementia and Alzheimer's disease increased as a cause of death over time (6.2% to 9.9%, MRR 1.19; 95% CI 0.96 to 1.48 in 2017 vs 2010). The CHA

conclusionsOur study reiterates that mortality after diagnosis of AF has decreased. The CHA

Indexed as

Atrial FibrillationCause of DeathRegistriesAgedAged, 80 and overAnticoagulantsFemaleFinlandHumansMaleMiddle AgedRetrospective StudiesAnticoagulantsadult cardiologycardiologycardiovascular diseaseelectronic health records

Identifiers

PMID39277207
PMCPMC11407195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.